DK2498771T3 - Anvendelse af bethanechol til behandling af xerostomi - Google Patents

Anvendelse af bethanechol til behandling af xerostomi

Info

Publication number
DK2498771T3
DK2498771T3 DK10779033.9T DK10779033T DK2498771T3 DK 2498771 T3 DK2498771 T3 DK 2498771T3 DK 10779033 T DK10779033 T DK 10779033T DK 2498771 T3 DK2498771 T3 DK 2498771T3
Authority
DK
Denmark
Prior art keywords
xerostomy
bethanechol
treatment
Prior art date
Application number
DK10779033.9T
Other languages
English (en)
Inventor
Nicola Cooper
Julian Clive Gilbert
Robert William Gristwood
Michael Grant Wyllie
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0919822A external-priority patent/GB0919822D0/en
Priority claimed from GBGB1004445.1A external-priority patent/GB201004445D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Application granted granted Critical
Publication of DK2498771T3 publication Critical patent/DK2498771T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK10779033.9T 2009-11-12 2010-11-11 Anvendelse af bethanechol til behandling af xerostomi DK2498771T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0919822A GB0919822D0 (en) 2009-11-12 2009-11-12 The treatment of salivary gland dysfunction
GBGB1004445.1A GB201004445D0 (en) 2010-03-17 2010-03-17 The treatment of salivary gland dysfunction
PCT/GB2010/051887 WO2011058366A1 (en) 2009-11-12 2010-11-11 Use of bethanechol for treatment of xerostomia

Publications (1)

Publication Number Publication Date
DK2498771T3 true DK2498771T3 (da) 2014-01-27

Family

ID=43382322

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10779033.9T DK2498771T3 (da) 2009-11-12 2010-11-11 Anvendelse af bethanechol til behandling af xerostomi

Country Status (23)

Country Link
US (3) US9149454B2 (da)
EP (1) EP2498771B1 (da)
JP (1) JP5595513B2 (da)
KR (1) KR20120092152A (da)
CN (1) CN102711752B (da)
AU (1) AU2010317747B2 (da)
BR (1) BR112012011086A2 (da)
CA (1) CA2780256A1 (da)
CY (1) CY1114766T1 (da)
DK (1) DK2498771T3 (da)
EA (1) EA022040B1 (da)
ES (1) ES2443847T3 (da)
HR (1) HRP20140020T1 (da)
IL (1) IL219613A (da)
MX (1) MX2012005456A (da)
NZ (1) NZ599880A (da)
PL (1) PL2498771T3 (da)
PT (1) PT2498771E (da)
RS (1) RS53124B (da)
SI (1) SI2498771T1 (da)
SM (1) SMT201400008B (da)
WO (1) WO2011058366A1 (da)
ZA (1) ZA201203289B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
CN111905188B (zh) 2015-02-18 2022-07-22 英赛罗公司 流体输送和输注装置及其使用方法
JP6472722B2 (ja) * 2015-06-30 2019-02-20 サンスター株式会社 口腔内投与する唾液分泌促進剤
WO2017123525A1 (en) 2016-01-13 2017-07-20 Bigfoot Biomedical, Inc. User interface for diabetes management system
EP3443998A1 (en) 2016-01-14 2019-02-20 Bigfoot Biomedical, Inc. Adjusting insulin delivery rates
EP3515535A1 (en) 2016-09-23 2019-07-31 Insulet Corporation Fluid delivery device with sensor
EP3568859A1 (en) 2017-01-13 2019-11-20 Bigfoot Biomedical, Inc. Insulin delivery methods, systems and devices
KR20200118128A (ko) * 2018-02-05 2020-10-14 셀릭스 바이오 프라이빗 리미티드 항무스카린제 또는 항콜린제 및 리포산의 조합 및 이의 용도
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
CA3099113A1 (en) 2018-05-04 2019-11-07 Insulet Corporation Safety constraints for a control algorithm-based drug delivery system
EP3856285A1 (en) 2018-09-28 2021-08-04 Insulet Corporation Activity mode for artificial pancreas system
US11565039B2 (en) 2018-10-11 2023-01-31 Insulet Corporation Event detection for drug delivery system
WO2020138559A1 (ko) * 2018-12-28 2020-07-02 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
USD920343S1 (en) 2019-01-09 2021-05-25 Bigfoot Biomedical, Inc. Display screen or portion thereof with graphical user interface associated with insulin delivery
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
KR20210044714A (ko) 2019-10-15 2021-04-23 인하대학교 산학협력단 노화기인 타액선 기능손상 회복을 위한 혈소판 풍부 혈장 기반 치료 조성물
US11957875B2 (en) 2019-12-06 2024-04-16 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
WO2023049900A1 (en) 2021-09-27 2023-03-30 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102340D0 (sv) 1991-08-13 1991-08-13 Astra Ab Pharmaceutical composition containing carbachol and othercholinergic substances
JP2683783B2 (ja) 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ZA9610154B (en) 1995-12-12 1997-06-17 Universiteit Van Preporia Mouthwash
GB9618341D0 (en) 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
CN100379423C (zh) * 1997-02-24 2008-04-09 S.L.A.药业股份公司 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20070190090A1 (en) 2006-02-07 2007-08-16 Whitehill Oral Technologies, Inc. Sialagogue based oral care products
WO2008100434A1 (en) 2007-02-09 2008-08-21 Durect Corporation Transoral dosage forms comprising sufentanil and naloxone

Also Published As

Publication number Publication date
AU2010317747A1 (en) 2012-05-31
US20120232137A1 (en) 2012-09-13
CN102711752B (zh) 2014-06-18
HRP20140020T1 (hr) 2014-02-14
SI2498771T1 (sl) 2014-04-30
US9149454B2 (en) 2015-10-06
ES2443847T3 (es) 2014-02-20
US20160287512A1 (en) 2016-10-06
EP2498771A1 (en) 2012-09-19
IL219613A (en) 2016-12-29
EA022040B1 (ru) 2015-10-30
JP5595513B2 (ja) 2014-09-24
NZ599880A (en) 2014-03-28
SMT201400008B (it) 2014-03-07
AU2010317747B2 (en) 2013-10-17
ZA201203289B (en) 2013-09-25
CY1114766T1 (el) 2016-12-14
EP2498771B1 (en) 2013-12-25
PT2498771E (pt) 2014-01-30
JP2013510840A (ja) 2013-03-28
CA2780256A1 (en) 2011-05-19
IL219613A0 (en) 2012-07-31
PL2498771T3 (pl) 2014-03-31
CN102711752A (zh) 2012-10-03
KR20120092152A (ko) 2012-08-20
BR112012011086A2 (pt) 2016-07-05
RS53124B (en) 2014-06-30
WO2011058366A1 (en) 2011-05-19
EA201270619A1 (ru) 2012-12-28
MX2012005456A (es) 2012-06-19
US10137084B2 (en) 2018-11-27
US20150366794A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
DK2629975T3 (da) Anordninger til fremstilling af væv
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2502172T3 (da) Hypoglykæmiske behandlingssystemer
DK2526425T3 (da) Fremgangsmåde til diagnosticering af endometriel receptivitet
DK3251678T3 (da) Benzoxaborolderivater til behandling af bakterieinfektioner
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
BR112012005382A2 (pt) inibidores de jak
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2501381T3 (da) Behandling af atrieflimmer
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen
BR112012021749A2 (pt) processos e compostos
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
DK2655360T3 (da) Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler
DK2424538T3 (da) Anvendelse af allopurinol til behandling af hånd-fod-hudreaktion
DK2455064T3 (da) Indretning til behandling af periodontal sygdom
DK2255893T3 (da) Indretning til behandling af biomasse
DK2531124T3 (da) Indretninger til behandling af hudlæsioner
DK2391366T3 (da) Substituerede benzimidazoler til behandling af astrocytomer
DK2566505T3 (da) Fremføring af kolesterylester til steroidogene væv
DK2451994T3 (da) Fremgangsmåde til fremstilling af et ioderende middel